OGN Stock Recent News
OGN LATEST HEADLINES
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
From a technical perspective, Organon (OGN) is looking like an interesting pick, as it just reached a key level of support. OGN recently overtook the 20-day moving average, and this suggests a short-term bullish trend.
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CALGARY, Alberta--(BUSINESS WIRE)--Matt Sjogren, President of CUPE 37 (City of Calgary outside workers) issued the following statement after employees rejected a contract settlement offer. Last night, the members of CUPE 37 rejected a memorandum of settlement of 9% wage increases over a three-year period. This vote sends a strong and clear message to the City of Calgary about the severe impact of inflation on our members. City employees are facing unprecedented financial challenges. Many are st.
SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $OGN #denosumabbiosimilar--European Medicines Agency validates Organon and Henlius marketing authorization filings for Prolia and Xgeva (denosumab) biosimilar candidate HLX14.
VITL, SFM, RCL, AEM and OGN are five stocks with explosive relative price strength.
Organon (OGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Organon, Pfizer, and Bristol Myers all offer yields above 5% and can compete with most Treasuries, but only Organon is up YTD. Spinoffs often struggle in their initial years, but Organon's partial reversal of its decline since Merck's castoff has been eye-catching, climbing over 40% YTD, and likely indicates changing sentiment. Independent from Merck, Organon is micromanaging for profit & growth, the products and global footprint that had been undermanaged by MRK.
Organon (OGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Organon (OGN) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $1.08 per share a year ago.